While hard science, and the need to sell it to the public and to protect it from government cuts, has grabbed much of the attention surrounding the 350th anniversary of the Royal Society, the UK’s self proclaimed premier science academy is not ignoring the commercial facts of life. Some of the £100 million that the Royal Society hopes to raise in its anniversary year is earmarked for Royal Society’s Enterprise Fund (RSEF) which is already backing new businesses based on research carried out in the UK.
It has never been easy for researchers who want to commercialise their science to raise money. This is especially true for anyone seeking relatively small amounts of money to fund the first steps towards commercialising an idea. “Apart from the government and regional funds virtually nobody is doing seed funding,” says Dr Andrew Mackintosh, Chief Executive of the RSEF.
“Getting that first-round money is really really difficult,” says Dr Mackintosh. A few venture capital funds would back an idea, from small to big as Mackintosh puts it, but those days are long gone. Thanks to the economic crisis, the issue has become even more pressing than it was four years ago, when the Royal Society started to think about its fund.
The RSEF has already looked at more than 200 ideas that were seeking backing, “and they keep rolling in,” says Dr Mackintosh. And this is despite taking a low key approach. “We are not pushing it hard,” says Dr Mackintosh. “The deal flow is very good already.” They also wanted to develop a modus operandi for what is a new activity for the Royal Society.
Current investments
So far, the fund has invested in three new businesses. The first of these, Novacem, is developing ‘carbon negative’ cement technology. The company has already picked up several awards, including a Science|Business ACES award, and signing up further investment from Lafarge, “the world leader in building materials”.
Earlier this year the fund also put money into Base4Innovation Ltd, which is based in Cambridge and is developing a new generation of ultra-fast DNA sequencing technology. The fund’s third investment was in Nano-Porous Solutions Ltd (n-psl), a ‘green’ air-filtration company developing research at the University of Bath in its Gateshead facilities.
So far the RSEF has put around £250,000 into each business it has backed. But this is not meant to be a particular pattern. “We don’t really have a minimum” for the amount the fund will invest, says Dr Mackintosh says that.
Philanthropic donations
Money to back these ventures came from philanthropic donations from wealthy individuals. So far the fund has raised some £6½ million of its target of £20 million. The idea is that the RSEF will be an evergreen fund. Any profits it makes will go back into the fund to support further ventures.
In its early days, the RSEF expects to concentrate on ideas from the physical sciences. In part this reflects the influence of Roger Brooke, one of the fund’s first donors. Brooke was a founder of Candover Investments and a founding director of IP Group.
As Dr Mackintosh puts it, the view is that physics based companies find it even harder to get funds than ideas in the life sciences, where there are already established sources of finance.
Evergreen fund
The idea of a self perpetuating evergreen fund is a part of the appeal to the people who put money into the fund, says Dr Mackintosh. “It is a very powerful model.” Donors like the notion that their money will carry on working.
Researchers seeking money also welcome the idea. “Academic founders particularly like the idea of us recycling our money,” says Dr Mackintosh.
Backing good ideas is just one of the goals that the Royal Society set for its fund. It also wants to influence thinking inside and outside the scientific community. The idea is that the name of the Royal Society will persuade other investors to support technology start-ups.
“Part of what we want to be able to do is to encourage and catalyse other investments into this area,” says Dr Mackintosh. He believes that there has already been some evidence of this. Other investors have backed ideas when they have seen that the RSEF is prepared to put money into them or even just to look kindly upon them.
Changing attitudes
The fund also hopes to change attitudes within the research community. In its early days, the Royal Society showed a healthy interest in turning science into profits. There was, though, a large gap of a couple of centuries, when many of the organisation’s fellows, make that Fellows, saw money making as a slightly mucky occupation. Such sentiments persisted until fairly recently.
Another of the fund’s goals is to accelerate this change attitudes, especially among the Fellows of the Royal Society who tend to be of an older generation than the younger researchers who now see it as natural to commercialise their own work. Here too the Royal Society is playing a part. A course in business matters is a part of the training for the bright young researchers on its scheme of University Research Fellowships for “outstanding scientists, who should have the potential to become leaders in their chosen field”.
A subtle way to change attitudes is for the fund to tap into the expertise of FRSs, drawing them into the assessment of commercial ideas. When it wants to check out a proposal, the RSEF can call on the knowledge of some of the brightest scientists in the country. And the nature of the Royal Society means that it can cover all scientific disciplines.
A commercial fund
For all of these ambitions, Dr Mackintosh insists that the RSEF is a commercial fund. It may not have to provide profits for investors, but it has to maintain the fund if it is to be able to invest not just in the start up of new ventures but also in their growth. The fund does not plan to severe its links with its companies as they grow. It was to be in a position to maintain a holding in the businesses.
It would not take many successes to replenish the RSEF. Dr Mackintosh is, though, accepts that it could take time. The physical sciences may not come up with ideas that take decades to shepherd through expensive clinical trials, but you cannot change the shape of a juggernaut like the cement industry overnight. Then again, the industry is so big that taking just a small share of the market could fuel the pipeline for quite a number of bright ideas.
No Comments »
Posted on Thursday, July 29th, 2010 at 5:33 pm


More Labnotes